Accessibility StatementSkip Navigation PHILADELPHIA  , Nov. 24, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Cepton, Inc. (NASDAQ: CPTN) ("Cepton" or the "Company") on behalf of investors who purchased or sold Cepton shares during the period of July 29, 2024 through January 6, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or sold Cepton securities during the Class Period may, no later than December 8, 2025, seek to ...

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc due to allegations of financial improprieties, including a multi-year accounting scheme that concealed losses and inflated profits [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Marex shares from May 16, 2024, to August 5, 2025 [1][2]. - Investors have until December 8, 2025, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against Marex - NINGI Research reported that Marex engaged in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions [3]. - The report highlighted discrepancies in intercompany receivables and loans across over 56 entities, amounting to multi-million-dollar differences [3]. - Marex allegedly concealed nearly $1 billion in off-balance-sheet derivatives, inflating operating cash flow by misclassifying structured note issuance as income [4]. Group 3: Market Reaction - Following the release of the report, Marex's stock price fell by $2.33, or 6.2%, closing at $35.31, resulting in significant investor losses [4].

Core Viewpoint - Jefferies Financial Group Inc. and its trade finance arm, Point Bonita Capital, are under investigation for potential violations of federal securities laws following a significant drop in stock price after revealing substantial exposure to First Brands Group, which recently filed for bankruptcy [2][4][6]. Group 1: Company Overview - Jefferies Financial Group Inc. is an investment banking and capital markets firm, with Point Bonita Capital serving as its trade finance division [4]. - Point Bonita Capital and Jefferies were closely associated with First Brands Group, an auto parts supplier that declared bankruptcy in September 2025 [4]. Group 2: Financial Exposure - On October 8, 2025, Jefferies disclosed that it and Point Bonita had approximately $715 million in exposure to First Brands' receivables, accounting for about 25% of Point Bonita's trade finance portfolio [5]. - Following this announcement, Jefferies' stock price fell by $4.66 per share, or approximately 8%, from $59.10 on October 7, 2025, to $54.44 on October 8, 2025 [5]. Group 3: Legal Investigation - Bleichmar Fonti & Auld LLP is investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors regarding their exposure to First Brands [6]. - Investors are reportedly seeking redemptions from Point Bonita in light of the situation [5].

INSPIRE NOTICE: Inspire Medical Systems, Inc. (INSP) Faces Securities Fraud Allegations after Stock Drops 32%, Investors Urged to Contact BFA LawNovember 24, 2025 6:08 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 24, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for securities fraud after ...

Core Viewpoint - James Hardie Industries plc (JHX) is facing a class action lawsuit for securities fraud following a significant stock drop of over 34% due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - A class action lawsuit has been filed against James Hardie and certain senior executives, asserting claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until December 23, 2025, to request to be appointed to lead the case, which is pending in the U.S. District Court for the Northern District of Illinois [3]. Group 2: Company Background - James Hardie is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Group 3: Stock Performance and Allegations - The company previously claimed strong performance in its North American fiber cement segment, stating it was seeing "normal stock levels" and expected performance [5]. - However, it was alleged that the sales were inflated due to inventory loading by channel partners, indicating fraudulent channel stuffing rather than genuine customer demand [5]. - On August 19, 2025, James Hardie reported a 12% decline in North American fiber cement sales, leading to a stock price drop from $28.43 to $18.64 per share, a decrease of $9.79 or over 34% [6]. Group 4: Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO [7].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 clinical trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, with investors having until December 15, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in MoonLake common stock [2]. Group 2: Company Background - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational drug sonelokimab [3]. - The company claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated a superior clinical response for patients compared to competitors [4]. Group 3: Clinical Trial Results - The VELA Phase 3 trials for sonelokimab reported disappointing results, with VELA-2 failing to meet its primary endpoint, raising concerns about the drug's regulatory approval and commercial viability [5][6]. - Following the announcement of the trial results on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - Beyond Meat, Inc. is under investigation for potential violations of federal securities laws, particularly concerning the inflation of the value of certain long-lived assets [1][3]. Financial Performance and Stock Movement - On October 24, 2025, Beyond Meat announced an expected non-cash impairment charge for the three months ended September 27, 2025, related to certain long-lived assets, which was anticipated to be material. This announcement led to a significant stock price drop of approximately 23%, from $2.84 per share on October 23, 2025, to $2.185 per share on October 24, 2025 [4]. - Following this, on November 3, 2025, the company delayed its earnings announcement for Q3 2025 due to the need for additional time to complete the impairment review, resulting in further declines in the stock price during trading on that day [5]. Company Operations and Asset Management - In late 2023, Beyond Meat conducted a global operations review and depreciated certain long-lived assets, stating that these assets were recorded at the lower of their carrying value or fair value less costs to sell, with no impairments reported [2].

Core Viewpoint - A class action lawsuit has been filed against James Hardie Industries plc and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - James Hardie Industries is a producer and marketer of high-performance fiber cement building solutions, primarily used in external siding for the residential building industry in the U.S. and Canada [4]. Allegations and Stock Performance - The lawsuit claims that James Hardie misrepresented the strength and momentum of its North American fiber cement segment, asserting that sales were driven by sustainable customer demand rather than inventory loading by channel partners [5]. - On August 19, 2025, James Hardie disclosed a 12% decline in North American fiber cement sales, attributed to destocking efforts by customers, leading to a stock price drop of over 34%, from $28.43 to $18.64 per share [6]. Legal Proceedings - Investors have until December 23, 2025, to request to lead the case in the U.S. District Court for the Northern District of Illinois, with the case titled Laborers' District Council and Contractors' Pension Fund of Ohio v. James Hardie Industries plc, et al. [3]. Management Changes - On November 17, 2025, it was announced that Rachel Wilson would step down from her role as CFO of James Hardie [7].

Core Viewpoint - CarMax, Inc. is facing a class action lawsuit for securities fraud following a significant drop in stock price attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit has been filed against CarMax and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 2, 2026, to request to lead the case in the U.S. District Court for the District of Maryland [3]. Group 2: Financial Performance - CarMax reported disappointing financial results for Q2 of fiscal year 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [6]. - The net income for Q2 was approximately $95.4 million, down from $132.8 million in the previous year [6]. Group 3: Stock Price Impact - Following the financial results announcement on September 25, 2025, CarMax's stock price dropped by $11.45 per share, or roughly 20%, from $57.05 to $45.60 [7]. - The unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 outlook led to an additional stock price drop of over 24% [7]. Group 4: Market Context - CarMax had previously promoted strong demand for its vehicles, which was allegedly inflated by a temporary surge in purchases before U.S. tariffs were imposed [4]. - The company attributed the sales declines to a "pull forward" in demand due to the tariff announcement [6].

Core Viewpoint - Senate Democrats are investigating Fiserv, Inc. and its former CEO Frank Bisignano regarding the company's failure to meet financial forecasts, which has raised concerns about potential misleading information to investors [1][2]. Group 1: Investigation Details - Lawmakers are seeking information on Bisignano's involvement in financial forecasting, his focus on short-term initiatives, and any internal reviews related to financial guidance [2]. - The investigation follows a securities fraud class action lawsuit after Fiserv's stock price dropped 47% on October 29, 2025, due to disappointing Q3 2025 results and reduced guidance [2][5]. - The lawsuit aims to represent investors who acquired Fiserv securities between July 23, 2025, and October 29, 2025, focusing on the accuracy of Fiserv's business statements and growth forecasts [3]. Group 2: Financial Performance - On July 23, 2025, Fiserv revised its 2025 organic revenue guidance to 10% and adjusted its EPS guidance to a low end of $10.15 [4]. - On October 29, 2025, Fiserv reported a sequential decline in Q3 2025 adjusted revenue, slashed organic revenue growth expectations to 3.5%-4%, and reduced EPS outlook to $8.50-$8.60 [5][6]. - The market reacted negatively, causing Fiserv's share price to drop over $59 in intraday trading, resulting in a loss of $32 billion in shareholder value [7]. Group 3: Management Changes - Following the disappointing results, Fiserv announced the departure of its CFO and a shake-up in its board of directors, with new leadership effective January 1, 2026 [5][6]. - The new CEO, Michael Lyons, indicated that the company had conducted a thorough analysis revealing overly optimistic growth assumptions in previous guidance [6].